The primary objective of this clinical trial is to assess the efficacy of rosiglitazone on
bare metal stent (BMS) in-stent restenosis measured as late lumen loss in patients with
metabolic syndrome.
The secondary parameter for evaluation of efficacy is binary restenosis.
The tertiary objective will be to assess the effect of rosiglitazone on major cardiac events
(MACE; death, MI, CABG, and target vessel revascularization). The occurrence of in-stent
restenosis for patients with metabolic syndrome who receive a DES in a non-target lesion will
be assessed angiographically at 9 months.